Bispecific M-CSF Antibody Dual Receptor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoporosis, such as bisphosphonates, have nonspecific adverse side effects and concerns regarding safety due to broad expression of target ligands, while targeting c-FMS and αvβ3 integrin individually has not progressed to clinical application effectively, and low-molecular-weight kinase domain inhibitors face challenges like toxicity and drug resistance.
Innovation Solution
Development of modified M-CSF polypeptides with an RGD motif that binds to both c-FMS and αvβ3 integrin, inhibiting osteoclast differentiation and bone resorption, which are designed to prevent dimerization and enhance binding affinity, thereby acting as a specific antagonist for these receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies targeting M-CSF or RANKL are used to inhibit osteoclast differentiation, then osteoporosis treatment efficacy is improved, but safety concerns arise due to expression of these ligands on cells other than osteoclasts
Solution Approach 1:
The patent merges two separate targeting approaches by creating a bispecific antibody that simultaneously binds to both c-FMS (M-CSF receptor) and αvβ3 integrin on osteoclasts. This dual-targeting strategy ensures high specificity to osteoclasts while avoiding off-target effects from single-antigen therapies, as both receptors are co-expressed primarily on osteoclasts.
Solution Approach 2:
The bispecific antibody performs multiple functions: it blocks M-CSF signaling through c-FMS binding and simultaneously inhibits osteoclast function through αvβ3 integrin binding. This multi-functional approach enhances both efficacy and safety by requiring dual receptor presence for therapeutic effect.
2Reliability
If low-molecular-weight kinase domain inhibitors targeting c-FMS are developed, then osteoclast activity inhibition is achieved, but challenges of toxicity and drug resistance occur
Solution Approach 1:
The patent uses a bispecific antibody as an intermediary that blocks signaling through both c-FMS and αvβ3 integrin simultaneously. This antibody-mediated approach avoids the toxicity and resistance issues associated with small-molecule kinase inhibitors while achieving effective osteoclast activity inhibition through receptor blockade.
3Reliability
If individual targeting of c-FMS or αvβ3 integrin is pursued, then osteoclast function inhibition is achieved, but clinical application progress is limited compared to dual targeting
Solution Approach 1:
The patent combines targeting of c-FMS and αvβ3 integrin into a single bispecific antibody molecule, achieving synergistic inhibition of osteoclast function. This merged approach accelerates clinical application progress by providing a comprehensive therapeutic mechanism in one agent rather than requiring combination therapies.
Data Source
AI summary
Mutant M-CSF protein, comprising αvβ3 integrin binding motif and pharmaceutical compositions comprising same, are provided. Further, use of the composition for the treatment and or prevention of diseases associated with increased bone resorption are provided.